Barclays views Illumina’s (ILMN) guidance last night as largely as expected. The bulls are going to defend the stock on China being de-risked, but Barclays still see risk with National ...

In a report released today, Luke Sergott from Barclays maintained a Sell rating on Illumina (ILMN – Research Report), with a price target of $100.00. The company’s shares closed yesterday at ...

Gene-sequencing giant Illumina is laying off 96 employees from its San Diego headquarters, according to paperwork filed with the state. This workforce reduction comes at a time when Illumina is ...

Sergott covers the Healthcare sector, focusing on stocks such as Illumina, Sotera Health, and Agilent. The word on The Street in general, suggests a Hold analyst consensus rating for Illumina with ...